Nobilis Salenvac T vaccine receives award at VIV Europe 2003

31 October 2003

Boxmeer, October 19, 2003 - Nobilis Salenvac T, Intervet’s new vaccine that provides excellent protection for breeder and layer birds against Salmonella infections has received the VIV award in the category "Animal Health". 

Nobilis Salenvac T was also one of the two nominees in the category "Food Safety", being an important advancement in efforts to make poultry meat and eggs safer for humans. 

Nobilis Salenvac T provides active immunization against S.enteritidis and S.typhimurium thus protecting commercial layer and breeder birds against the health implications of salmonella infections. In addition, research has shown that maternal antibodies passed from the vaccinated breeder birds to their progeny protect chicks against salmonella infections during their first weeks of life. 

Nobilis Salenvac T offers poultry producers the benefits of broadest possible protection against a wide range of salmonella strains with the use of just one vaccine. It is therefore a major advancement in efforts to make poultry meat and eggs safer for human consumption. 

It joins the Nobilis family of Safe Poultry products, which includes Salenvac and SG 9R. Available in the U.K. since January 2003, Salenvac T will be introduced throughout Europe in early 2004. 

The VIV Europe, taking place every two years in Utrecht, The Netherlands is an international trade fair, which serves as a major platform for the international livestock industry. The VIV award selects most innovative product in different categories while also considering l the social relevance of the new products or services. 

Further information: 

Mr. Ruud Aerdts, Marketing Manager Poultry Products
e-mail address:Ruud.Aerdts@intervet.com

Note for the editor: 

Intervet, a business unit of Akzo Nobel, headquartered in Boxmeer, The Netherlands, with sales of EUR 1,081 million in 2002, is focused on the research and development, manufacturing and marketing of veterinary products. Products include vaccines for the prevention of infectious diseases, anti-infectives, anti-parasitics, pharmaceutical specialities and products for fertility management. All of these products are intended for use in a variety of animal species, including poultry, pigs, cattle, sheep, goats, horses, fish and companion animals. Intervet operates globally with its own marketing organizations. The company currently employs around 5,000 people. 

Internet: www.intervet.com 

Akzo Nobel, based in the Netherlands, serves customers throughout the world with healthcare products, coatings and chemicals. Consolidated sales for 2002 totaled EUR 14 billion. The Company currently employs approximately 65,200 people in more than 80 countries. Financial results for 2003 will be published on February 3, 2004. 

Internet: www.akzonobel.com